Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Meeting of the expert committee on the use of pre-mixed insulin preparation Humalog Mix 50 in type 2 diabetes mellitus

Cover Page

Abstract


The panel of experts has a held a discussion on effectiveness and tactics of glycemic control by pre-mixed insulin preparations in T2DM. Special attention was paid to the aspects of treatment with Humalog Mix 50, including indications and contraindications, potential for the achievement of therapeutic goals and optimization of patient monitoring.

Endocrinology Research Centre, Moscow

Author for correspondence.
Email: post@endocrincentr.ru

Russian Federation

  1. Шестакова МВ. Программа A1chieve в России: многоцентровое проспективное наблюдательное исследование эффективности и безопасности начала и интенсификации инсулинотерапии с помощью аналогов инсулина у пациентов с сахарным диабетом 2 типа, ранее не получавших инсулин, в повседневной клинической практике. Сахарный диабет. 2012;(1):63–70. [Shestakova MV. A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who start and intensify insulin treatment having never received it before. Diabetes mellitus. 2012;(1):63–70. doi: 10.14341/2072-0351-5981 ].
  2. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28(11):2673–26739.
  3. doi: 10.2337/diacare.28.11.2673
  4. Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. Health Qual Life Outcomes. 2007;5(1):69.
  5. doi: 10.1186/1477-7525-5-69.
  6. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation andadjustment of therapy: a consensus statement from the American Diabetes Association and the EuropeanAssociation for the Study of Diabetes. Diabetologia 2009. 52:17–30.
  7. doi: 10.1007/s00125-008-1157-y
  8. Дедов ИИ, Шестакова МВ. Оптимизация и интенсификация инсулинотерапии при СД 2 типа (клинические рекомендации). Сахарный диабет. 2010;(5):9–16. [Dedov II, Shestakova MV. Optimizatsiya i intensifikatsiya insulinoterapii pri sakharnom diabete 2 tipa (klinicheskie rekomendatsii). Diabetes mellitus. 2010; (5): 9–16. doi: 10.14341/2072-0351-6049 ].
  9. Rosenstok J, Ahmann AJ, Colon G, Scism-Bacon J, et al. Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents. Diabetes Care 2007;31(1):20–25.
  10. doi: 10.2337/dc07-1122
  11. Jain SM, Mao X, Escalante-Pulido M, Vorokhobina N, et al. Prandial–basal insulin regimens plus oralantihyperglycaemic agents to improve mealtime glycaemia:initiate and progressively advance insulin therapy in type 2diabetes. Obesity et Metabolism 2010;12(11):967–75.
  12. DOI: 21111/j.1463-1326.2010.01287.x

Views

Abstract - 1246

PDF (Russian) - 1713

HTML (Russian) - 935

Cited-By


PlumX


Copyright (c) 2013 .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies